Global Sphygmomanometer Market - 2025-2033

Global Sphygmomanometer Market: Industry Outlook

The global sphygmomanometer market reached US$ 3.12 Billion in 2023, with a rise of US$ 3.37 Billion in 2024 and is expected to reach US$ 7.17 Billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

The global sphygmomanometer market is experiencing significant growth due to the increasing prevalence of hypertension and cardiovascular diseases. As lifestyle-related disorders become more prevalent, the need for accurate blood pressure monitoring is becoming more critical. This has led to a surge in demand for both manual and electronic sphygmomanometers in hospitals, clinics, ambulatory care centers, and home healthcare settings.

Technological innovations, such as digital blood pressure monitors with automated features, Bluetooth connectivity, and AI-based analytics, are revolutionizing patient monitoring by offering real-time data, improved accuracy, and enhanced usability. The integration of these devices with smartphones and telemedicine platforms strengthens their role in remote patient care and chronic disease management.

North America currently dominates the market due to its advanced healthcare infrastructure, high health awareness, and focus on preventive care. The Asia Pacific region is emerging as the fastest-growing market due to a large patient population, increasing healthcare expenditures, and rising awareness about hypertension and self-monitoring.

Global Sphygmomanometer Market Dynamics: Drivers & Restraints

Driver: Rising prevalence of hypertension and cardiovascular diseases

The global prevalence of hypertension and cardiovascular diseases (CVDs) is driving the growth of the sphygmomanometer market. Hypertension, a major risk factor for serious health complications, affects over a billion people worldwide. Factors such as sedentary lifestyles, unhealthy diets, rising obesity rates, stress, and aging populations contribute to the burden of these conditions.

As a result, there is a growing need for accurate blood pressure monitoring for early detection, management, and timely medical intervention. Sphygmomanometers, particularly portable and home-use digital models, are becoming essential tools for individuals and healthcare providers to monitor blood pressure consistently. Governments and healthcare organizations are promoting awareness and screening initiatives to boost device adoption.

For instance, according to the Centers for Disease Control and Prevention, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. One person dies every 33 seconds in the United States from cardiovascular disease.

Hence, the high mortality rate in the US has heightened awareness of the need for early detection and management of cardiovascular conditions, leading to a surge in the use of sphygmomanometers for regular blood pressure monitoring.

Driver: Technological advancements in digital and wearable sphygmomanometers

Technological advancements in the consumer healthcare category, such as innovations in wearable technology, apps, and mobiles, as well as reducing average selling prices for retailers and manufacturers, are boosting market growth. The accuracy and reliability of sphygmomanometers are increased by advancements in digital technology and sensors. Higher accuracy in measurements leads to improved patient care and diagnosis, which drives up demand for these devices.

Manufacturers are advancing the devices to make them more convenient for patients to incorporate in homecare settings as well as for healthcare practitioners to increase the accuracy of finding the patient’s health conditions.

For instance, in February 2024, Hanvon Technology Co., Ltd., launched the world’s first smart electronic BP Meter utilizing the Korotkoff sound method. This device integrates advanced sensor technology with artificial intelligence algorithms and overcomes the accuracy limitations of traditional electronic BP meters.

Also, on June 5, 2024, Konica Minolta, Inc. announced that the Company will launch the CM-17d and CM-16d vertical, lightweight, portable spectrophotometers capable of high-accuracy measurement in the summer of 2024.

Restraint: Product recalls and accuracy issues with low-quality devices

The global sphygmomanometer market faces challenges due to product recalls and accuracy issues. The demand for affordable blood pressure monitors, especially in developing markets, has led to a surge in unregulated and substandard devices. These devices often fail to meet international accuracy standards, leading to inaccurate readings and potential misdiagnosis. This undermines manufacturers' credibility, raises legal and regulatory risks, and erodes consumer trust.

For instance, in October 2024, a product called MEDLINE Automatic Digital Blood Pressure Monitor with a faulty microchip was found to fail to power on, display screen issues after initial use, and occasionally overheat, making the unit warm to the touch.

Opportunity: Integration of AI and IoT in blood pressure monitoring devices

The integration of Artificial Intelligence (AI) and the Internet of Things (IoT) in blood pressure monitoring devices is revolutionizing the global sphygmomanometer market. These technologies enable real-time data collection, analysis, and personalized insights, detecting patterns, predicting health risks, and offering actionable recommendations. AI algorithms can also provide early intervention for chronic conditions like hypertension.

The growing trend of remote patient monitoring and telemedicine is driving the demand for AI- and IoT-enabled devices, supporting virtual care delivery. These smart devices enhance patient engagement, optimize clinical decision-making, and reduce hospital visits. As healthcare systems move towards digitization and data-driven care, the integration of AI and IoT in sphygmomanometers is unlocking significant growth potential and reshaping blood pressure monitoring, management, and treatment.

Global Sphygmomanometer Market Segment Analysis

The global sphygmomanometer market is segmented based on product type, operation, end user, and region.

Product Type

The electronic sphygmomanometer segment from the product type is expected to hold 43.10% of the sphygmomanometer market

An electronic sphygmomanometer is a medical device that automatically measures blood pressure without a stethoscope, consisting of an inflatable cuff, pressure sensor, and digital display screen, widely used in clinical, home, and remote healthcare settings.

The electronic sphygmomanometer segment is experiencing strong growth due to factors such as increasing preference for home-based blood pressure monitoring, hypertension awareness, and ease of use. Consumers are drawn to electronic sphygmomanometers for their automatic inflation, digital displays, and memory storage features. The integration of Bluetooth and wireless connectivity allows real-time health tracking through smartphones and remote patient monitoring platforms, especially in the post-pandemic era.

For instance, in April 2024, Omron launched its inaugural manufacturing plant in Chennai, Tamil Nadu. It is a Japanese medical device company known for its electronic blood pressure monitors. An estimated ₹128 crore has been invested in the plant currently under construction.

As healthcare systems shift towards preventive and personalized care, electronic sphygmomanometers are essential tools for early detection and continuous monitoring of cardiovascular conditions. Technological advancements, falling device costs, and greater availability through e-commerce channels are making these devices more accessible to a broader population, further propelling market growth in this segment.

Global Sphygmomanometer Market - Geographical Analysis

North America dominated the global sphygmomanometer market with the highest share of 42.3% in 2024

The North American sphygmomanometer market is fueled by the region's established healthcare infrastructure, high awareness of hypertension, FDA approvals, and emphasis on preventive healthcare. The US has a significant patient population with chronic conditions like hypertension, cardiovascular diseases, and diabetes, necessitating regular blood pressure monitoring.

For instance, in November 2024, OMRON Healthcare received FDA approval to market new home blood pressure monitors with AI-powered atrial fibrillation detection, a key solution to the growing AFib epidemic. The IntelliSense™ AFib algorithm analyzes the pressure pulse wave generated during blood pressure measurement to detect AFib, a leading cause of stroke.

Moreover, the region has seen a rapid uptake of advanced digital and automated blood pressure monitors, often integrated with mobile applications and wearable devices. Leading medical device manufacturers in the region encourage innovation and ensure a steady supply of high-quality monitoring equipment. The COVID-19 pandemic has further boosted the use of home-use digital sphygmomanometers. North America's regulatory support, increasing geriatric population, and high health spending make it a dominant market for sphygmomanometer manufacturers.

Asia-Pacific is the global sphygmomanometer market with a market share of 21.5% in 2024

The Asia Pacific sphygmomanometer market is experiencing rapid growth due to increasing disease prevalence, health awareness, and healthcare access improvements. The region's aging population, particularly in Japan, China, and South Korea, contributes to higher hypertension and cardiovascular conditions. Urbanization and lifestyle changes are increasing hypertension risk, prompting increased adoption of blood pressure monitoring devices. Governments are investing in primary healthcare systems and rural outreach, creating new opportunities for affordable and portable sphygmomanometers. Digital devices from regional manufacturers, particularly in China and India, are making home-based monitoring more accessible to middle- and lower-income populations.

For instance, in March 2025, Sky Labs signed a distribution agreement with OMRON Healthcare, marking a significant expansion into Japan's consumer health market. The deal will bring the medical wearable startup's smart ring-based blood pressure monitor to Japan by the end of the year.

Global Sphygmomanometer Market - Key Players

The major global players in the sphygmomanometer market include Merck & Co., Inc., Johnson & Johnson, Sanofi, CSL Limited, Serum Institute of India Pvt. Ltd., AstraZeneca, Bavarian Nordic Inc., BioDiem, and Bharat Biotech, among others.

Global Sphygmomanometer Market – Key Developments

• In October 2024, Scottish tech firm Novosound developed the world's first ultrasonic blood pressure monitor, enabling cuffless, wearable blood pressure monitoring with accuracy comparable to conventional devices. This follows a collaboration with the Texas Medical Center, aiming to revolutionize blood pressure monitoring in wearables.

• In July 2024, Smart Meter, a leading provider of Cellular Remote Patient Monitoring (RPM) solutions, launched its first cellular-connected, multi-cuff blood pressure monitor specifically designed for RPM and chronic care management. This innovative device offers unparalleled accuracy, inclusivity, and comprehensive health insights for the 129 million Americans living with chronic illnesses.